Ceftaroline
General
- Type: Antibiotic, Cephalosporin (fifth generation)
- Dosage Forms: IV
- Common Trade Names: Teflaro
Adult Dosing
- Pneumonia, Community-acquired: IV: 600 mg every 12 hours for 5 to 7 days
- Skin and skin structure infection: IV: 600 mg every 12 hours for 5 to 14 days
Pediatric Dosing
- Cystic Fibrosis pulmonary exacerbation, MRSA:
- Children ≥ 6 years old - IV 15 mg/kg/dose every 8 hours (max dose 600 mg/dose)
- Pneumonia, community acquired:
- ≥ 2 months - < 2 years age - IV 8 mg/kg/dose every 8 hours for 5-14 days
- ≥ 2 years - < 18 years
- ≤ 33 kg: IV 12 mg/kg/dose every 8 hours for 5-14 days
- > 33 kg: IV 400 mg every 8 hours OR 600 mg every 12 hours for 5-14 days
- Skin and skin structure infection:
- ≥ 2 months - < 2 years age - IV 8 mg/kg/dose every 8 hours
- ≥ 2 years - < 18 years
- ≤ 33 kg: IV 12 mg/kg/dose every 8 hours
- > 33 kg: IV 400 mg every 8 hours OR 600 mg every 12 hours
Special Populations
- Pregnancy Rating:
- Adverse events have been observed in animal studies
- Lactation:
- Unknown if excreted in breast milk. Manufacturer recommends to use caution when giving to nursing women.
- Renal Dosing
- Adult
- CrCl > 50 mL/minute: No dosage adjustment necessary
- CrCl > 30 to ≤ 50 mL/minute: 400 mg every 12 hours
- CrCl ≥ 15 to ≤ 30 mL/minute: 300 mg every 12 hours
- CrCl < 15 mL/minute: 200 mg every 12 hours
- ESRD patients on hemodialysis: 200 mg every 12 hours; dose given after hemodialysis on dialysis days
- Pediatric
- ≥ 2 months to < 18 years of age
- CrCl > 50 mL/minute/1.73 m²: No adjustment necessary
- CrCl ≤ 50 mL/minute/1.73 m²: Insufficient data, use with caution, dosing adjustment may be necessary
- ≥ 18 years of age - same as adult dosing
- ≥ 2 months to < 18 years of age
- Adult
- Hepatic Dosing
- Adult
- No dosage adjustment in manufacturer's labeling. Has not been studied.
- Pediatric
- No dosage adjustment in manufacturer's labeling. Has not been studied.
- Adult
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- C. diff
- Elevated ALT/SGPT, hepatitis
- Anaphylaxis, hypersensitivity reaction
- Seizure
- Renal failure
Common
Pharmacology
- Half-life:
- 1.6 ± 0.38 hours (single dose), 2.66 ± 0.4 hours (multiple doses)
- Metabolism:
- Excretion:
- Urine 88%, Feces 6%
- Mechanism of Action:
- Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014
Ceftaroline: Drug information. UpToDate. www.uptodate.com. Accessed April 1, 2019.